Will TSS segment trailing-twelve-months Adjusted EBITDA fall below $600M as disclosed by the Q3 2026 10-Q?
Current Prediction
Why This Question Matters
The critical operational offset market. Management guided double-digit TSS growth in H1 2026. A TTM EBITDA fall below $600M (from $670M FY2025) would invalidate that guide, undermine Moat Mapper DEFENSIBLE, and raise EXPECTATIONS_PRICED pressure. Opteon is the single most important forward-looking earnings pillar; its trajectory determines whether the HIGHER_SCRUTINY classification has an Opteon-supported floor or not.
Prediction Distribution
Individual Predictions(9 runs)
FY2025 TSS EBITDA $670M, management guided double-digit H1 2026 growth. For Q3 2026 TTM to fall below $600M requires 10.4% decline from FY2025 baseline. That implies: Q4 2025 (part of TTM) + Q1-Q3 2026 produce <$600M. Q4 2025 was part of the +17% growth year, so it was strong. Q1-Q3 2026 would need to be substantially weaker than FY2025 quarters to drag TTM under $600M. Given management's double-digit H1 guide, insider accumulation, and structural tailwinds, only a macro shock, major customer bankruptcy, or input-cost reversal would produce this outcome. Probability ~20%. Mean-reversion from 32% peak margin adds some upside risk to YES. Settle 0.22.
Revealed-preference signals (SG&A buildout, insider accumulation, double-digit H1 guide, AIM Act regulatory tailwind, patent-protected Opteon duopoly, customer qualification inertia) all argue against -10% TTM. HVAC inventory replenishment in H1 is a high-conviction call tied to housing market recovery dynamics. Even if mean reversion is real, typical reversion from 32% margin is gradual (50-100bps/yr), not step-function decline. 0.18 reflects skeptical view that this outcome would require a genuine macro or company-specific shock.
Upward adjustment for: (a) AI capex pullback could hurt data center cooling leg, (b) Honeywell Solstice price competition could compress margin, (c) residential HVAC recovery timing uncertain given rate environment, (d) aftermarket strength may be peak. A confluence of mild headwinds could produce TTM decline of 8-12%, which is within the crossing range. 0.25 captures upside optionality on the NO thesis.
FY2025 at $670M with +17% growth + tailwinds + H1 double-digit guide. To cross sub-$600M TTM requires meaningful deterioration. Base rate for specialty chemical segments to decline 10%+ in one year when entering with +17% momentum and structural tailwinds is low, ~15-25%. 0.20.
Management guide + tailwinds support continued growth. Risks: margin peak mean reversion + residential HVAC recovery timing + data center cooling cyclicality. Settle 0.22 reflecting modest downside probability.
Slightly elevated from pure base rate given committee's EXPECTATIONS_PRICED DEMANDING read — consensus is confident on TSS, which creates modest contrarian setup. However, revealed preferences still support growth. 0.24.
Strong FY2025 momentum + tailwinds + guide support NO. Probability of YES (sub-$600M TTM) ~20-25% reflecting tail risks. Settle 0.22.
Base rate 20-25% for tail decline scenario given strong baseline. 0.21.
Tail probability for material deterioration in a strong-momentum segment: 20-25%. Mid 0.23.
Resolution Criteria
Resolves YES if the Q3 2026 10-Q (filed approximately November 2026) or Q3 2026 earnings release by 2026-11-30 discloses TSS segment trailing-twelve-months Adjusted EBITDA below $600M (calculated as sum of Q4 2025 + Q1 2026 + Q2 2026 + Q3 2026 Adjusted EBITDA). Resolves NO if (a) disclosed TSS TTM Adjusted EBITDA at Q3 2026 is $600M or higher, (b) TSS segment reporting is reorganized with no clean disclosure, or (c) no Q3 2026 disclosure is made by 2026-11-30.
Resolution Source
Chemours Q3 2026 10-Q, Q3 2026 earnings release and conference call
Source Trigger
TSS (Opteon) Segment EBITDA Trajectory — TSS EBITDA growth below 10% or absolute EBITDA below $600M; Opteon is the critical offset to TT/APM drag
Full multi-lens equity analysis